(Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the ...
Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 ...
(“NEXGEL” or the “Company”) (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team ...
Secures agreement pausing conversion rights until January 2027 (unless closing share price equals or exceeds $0.275) and ...
In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...
Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife ...
Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced that Azeem Latib, MD, ...
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines ...
NEWARK, CA / ACCESS Newswire / October 27, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") ...
Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ...
Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its ...
Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results